Orion Pharma has entered into a licensing agreement with the Population Council, an international, nonprofit U.S.-based organization, providing Orion Pharma worldwide exclusive rights to develop, manufacture, market, sell, and sublicense the synthetic progestin, Nestorone, for hormone replacement therapy (HRT) in transdermal dosage forms other than the patch. Nestorone is a new chemical entity that is Read more about Orion Pharma Gains Rights To Nestorone In Transdermal Gels[…]